<p>低市值生物科技公司是一种高风险但高回报的投资选择。如果它们的临床试验取得成功，这往往意味着价值会激增，因为投资者预期会有收购。</p>
<p>然而，如果它们失败，这可能意味着这些公司的终结。以下是一份定价低于 10 美元的有潜力的生物科技公司名单，它们可能在未来几个月内提供巨大的投资回报。</p>
<h2>Actinium Pharmaceuticals (ATNM)</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Shutterstock</p>
<p><strong>Actinium Pharmaceuticals</strong>（NYSEMKT：<strong>ATNM</strong>）是一家生物科技公司，致力于为失败现有治疗的癌症患者提供靶向放射治疗。</p>
<p>其当前产品管线是针对处于第 3 期临床试验中的产品。这些产品针对老年人，患有活动性复发性或难治性急性髓样白血病。</p>
<p>华尔街分析师对这家处于临床阶段的生物科技公司非常乐观。他们给出了平均价格目标为 25.60 美元，根据最近约 7 美元的股价，意味着上涨了 267.82%。最乐观的分析师预测股价将达到 50 美元，上涨潜力为 618.39%。</p>
<p>对于 2024 财年，分析师预测每股亏损 1.73 美元。这是与去年每股 1.83 美元的亏损相比的重大改善。虽然预计 Actinium 在 2024 年不会产生实质性销售额，但分析师预测如果其临床阶段试验成功，到 2025 年将会有巨额销售额。这使其成为生物科技行业最具吸引力的低于 10 美元的股票之一。</p>
<h2>Iovance Biotherapeutics (IOVA)</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Gorodenkoff / Shutterstock.com</p>
<p><strong>Iovance Biotherapeutics</strong>（NASDAQ：<strong>IOVA</strong>）致力于开发创新的癌症治疗，涉及肿瘤浸润性白细胞的发展。这些细胞会杀死体内的有缺陷细胞。然而，它们有时需要帮助才能正确执行其职责。</p>
<p>该公司已获得一种名为 Amtagvi 的批准疗法，该疗法于 2 月获得 FDA 批准。目前仅批准用于一部分黑色素瘤患者。然而，Iovance 还有其他五项临床试验可与该治疗一起使用。它在各种研究阶段中有一长串治疗方案。</p>
<p>在 2023 年初，该公司获得了 Proleukin 的权利，这是一种已获 FDA 批准的白细胞介素-2 产品。除了有助于促进收入增长外，新获得的药物在与 Amtagvi 联合使用时促进了更好的反应。</p>
<p>在其 2024 财年第一季度业绩中，Iovance Biotherapeutics 报告称已有 100 多名患者接受了使用 Amtagvi 的治疗方案。该公司还预计将获得在欧盟、英国和加拿大使用该药物的批准。</p>
<p>已经上市两种药物并且有更多临床试验在进行中，IOVA 股票可能会在未来几个月内价值激增。分析师对其未来持乐观态度。他们预测每股平均价格目标为 25.58 美元，根据最近 7.28 美元的股价，上涨了 230.92%。在预测的最高端，最乐观的分析师预计每股 34 美元，上涨 339.84%。</p>
<h2>Geron (GERN)</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：shutterstock.com/Romix Image</p>
<p><strong>Geron</strong>（NASDAQ：<strong>GERN</strong>）是一家临床生物制药公司，致力于开发和商业化血液癌症治疗。其主要产品是处于第 3 期临床试验中的端粒酶抑制剂。它抑制了血液中的癌细胞的进展。</p>
<p>6 月，Geron 宣布获得 Rytelo（Imetelstat）在患有输血依赖性贫血的低风险骨髓增生异常综合征（MDS）患者中使用的批准。</p>
<p>根据其 2024 财年第一季度业绩，该公司拥有 4.65 亿美元的流动性，为其提供了充足的空间来操作和支持现有试验。与 2023 年第一季度的 21,000 美元相比，其收入也大幅增长至 304,000 美元。</p>
<p>该公司还预测，它仍有足够的资源支持运营，直到 2026 年第二季度。在 Imetelstat 获得在美国使用批准后，该公司可能会改善其第二季度的收入前景。</p>
<p>Imetelstat 是 <strong>Merck</strong>（NYSE：<strong>MRK</strong>）和 <strong>Bristol-Myers Squibb</strong>（NYSE：<strong>BMY</strong>）产品的直接竞争对手。这使得 Geron 成为被收购的主要候选公司。鉴于肿瘤学的并购活动在医疗保健领域非常流行，GERN 投资者在收购时可能会看到股价大幅提升。分析师对 GERN 持乐观态度。他们给予该股票平均价格目标为 6.81 美元，根据最近 4.53 美元的股价，上涨了 63.31%。在预测的最高端，分析师预测 10 美元，上涨了 139.81%。</p>
<p><em>在发布日期，Joel Lim 在本文提到的证券中没有（直接或间接）任何头寸。本文中表达的观点属于作者本人，遵守 InvestorPlace.com 的发布准则。</em></p>
<p><em>在发布日期，负责编辑在本文提到的证券中没有（直接或间接）任何头寸。</em></p>
<p>Joel Lim 是 InvestorPlace.com 的撰稿人，也是一名金融内容承包商，为 LTSE 和 Realtor 等多家公司以及 Business Insider、Yahoo Finance、Mises Institution 和 Foundation for Economic Education 等金融出版物创作内容。</p>
<p>医疗保健、生物科技</p>
<p>成长股、低估股票</p>

杰龙公司

<p>被定价低于 10 美元的小市值生物科技公司被视为高风险但高回报的投资选择。Actinium Pharmaceuticals（ATNM）、Iovance Biotherapeutics（IOVA）和 Geron（GERN）被提及为有潜力获得显著回报的有前景的生物科技公司。这些公司正在开发创新的癌症治疗方法，并且其产品正在进行第三阶段临床试验。分析师对它们的未来持乐观态度，预期有价格目标和潜在的收购机会</p>

<p>Low-cap biotech companies are a high-risk but high-reward investment choice. If their clinical trials are successful, that can often mean an explosion in value as investors anticipate a buyout.</p>
<div class="lb-trans"><p>低市值生物科技公司是一种高风险但高回报的投资选择。如果它们的临床试验取得成功，这往往意味着价值会激增，因为投资者预期会有收购。</p>
</div><p>However, if they fail, that may mean the end of the road for these companies. Here is a list of promising biotechs priced under $10 that could offer a huge return on investment in the coming months.</p>
<div class="lb-trans"><p>然而，如果它们失败，这可能意味着这些公司的终结。以下是一份定价低于 10 美元的有潜力的生物科技公司名单，它们可能在未来几个月内提供巨大的投资回报。</p>
</div><h2>Actinium Pharmaceuticals (ATNM)</h2>
<div class="lb-trans"><h2>Actinium Pharmaceuticals (ATNM)</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>来源：Shutterstock</p>
</div><p><strong>Actinium Pharmaceuticals</strong> (NYSEMKT: <strong>ATNM</strong>) is a biotech working on target radiotherapy treatment for cancer patients who failed existing treatments.</p>
<div class="lb-trans"><p><strong>Actinium Pharmaceuticals</strong>（NYSEMKT：<strong>ATNM</strong>）是一家生物科技公司，致力于为失败现有治疗的癌症患者提供靶向放射治疗。</p>
</div><p>Its current product pipeline is for products that are in Phase 3 clinical trials. These are targeted at the elderly with active relapsed or refractory acute myeloid leukemia.</p>
<div class="lb-trans"><p>其当前产品管线是针对处于第 3 期临床试验中的产品。这些产品针对老年人，患有活动性复发性或难治性急性髓样白血病。</p>
</div><p>Wall Street analysts are quite optimistic about this clinical-stage biotech. They give it an average price target of $25.60, implying 267.82% upside based on the most recent price of around $7 per share. The most optimistic analysts forecast a price of $50, or 618.39% upside potential.</p>
<div class="lb-trans"><p>华尔街分析师对这家处于临床阶段的生物科技公司非常乐观。他们给出了平均价格目标为 25.60 美元，根据最近约 7 美元的股价，意味着上涨了 267.82%。最乐观的分析师预测股价将达到 50 美元，上涨潜力为 618.39%。</p>
</div><p>For fiscal 2024, the analysts forecast a loss per share of $1.73. That is a major improvement from last year’s $1.83 loss per share. While Actinium is not expected to generate meaningful sales in 2024, analysts forecast huge sales in 2025 if its clinical stage trial succeeds. That makes it amongst the biotech industry’s most lucrative under $10 stocks.</p>
<div class="lb-trans"><p>对于 2024 财年，分析师预测每股亏损 1.73 美元。这是与去年每股 1.83 美元的亏损相比的重大改善。虽然预计 Actinium 在 2024 年不会产生实质性销售额，但分析师预测如果其临床阶段试验成功，到 2025 年将会有巨额销售额。这使其成为生物科技行业最具吸引力的低于 10 美元的股票之一。</p>
</div><h2>Iovance Biotherapeutics (IOVA)</h2>
<div class="lb-trans"><h2>Iovance Biotherapeutics (IOVA)</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Gorodenkoff / Shutterstock.com</p>
<div class="lb-trans"><p>来源：Gorodenkoff / Shutterstock.com</p>
</div><p><strong>Iovance Biotherapeutics</strong> (NASDAQ: <strong>IOVA</strong>) is working on innovative cancer treatments that entail the development of tumor-infiltrating white blood cells. These cells kill faulty cells in the body. However, they sometimes need help figuring out how to perform their duties correctly.</p>
<div class="lb-trans"><p><strong>Iovance Biotherapeutics</strong>（NASDAQ：<strong>IOVA</strong>）致力于开发创新的癌症治疗，涉及肿瘤浸润性白细胞的发展。这些细胞会杀死体内的有缺陷细胞。然而，它们有时需要帮助才能正确执行其职责。</p>
</div><p>It has one approved therapy called Amtagvi, which received FDA approval in February. It is currently only approved for a subset of melanoma patients. However, Iovance has five other clinical trials for use with this treatment. It has a long list of treatments in various phases of study.</p>
<div class="lb-trans"><p>该公司已获得一种名为 Amtagvi 的批准疗法，该疗法于 2 月获得 FDA 批准。目前仅批准用于一部分黑色素瘤患者。然而，Iovance 还有其他五项临床试验可与该治疗一起使用。它在各种研究阶段中有一长串治疗方案。</p>
</div><p>In early 2023, the company acquired rights to Proleukin, an interleukin-2 product that has received FDA approval. Besides helping promote revenue growth, the newly acquired drug promotes a better response when combined with Amtagvi.</p>
<div class="lb-trans"><p>在 2023 年初，该公司获得了 Proleukin 的权利，这是一种已获 FDA 批准的白细胞介素-2 产品。除了有助于促进收入增长外，新获得的药物在与 Amtagvi 联合使用时促进了更好的反应。</p>
</div><p>In its first quarter fiscal 2024 results, Iovance Biotherapeutics reported over 100 patients were enrolled into a treatment regime using Amtagvi. The company also expects to receive approval for the use of the drug in the EU, U.K., and Canada.</p>
<div class="lb-trans"><p>在其 2024 财年第一季度业绩中，Iovance Biotherapeutics 报告称已有 100 多名患者接受了使用 Amtagvi 的治疗方案。该公司还预计将获得在欧盟、英国和加拿大使用该药物的批准。</p>
</div><p>With two drugs already on the market and more clinical trials in the pipeline, IOVA shares could see an explosion in value in the coming months. Analysts are optimistic about its future. They forecast an average price target of $25.58 per share, a 230.92% upside based on the most recent price of $7.28. On the upper end of the forecast, the most optimistic analysts expect $34 per share, which is a 339.84% upside.</p>
<div class="lb-trans"><p>已经上市两种药物并且有更多临床试验在进行中，IOVA 股票可能会在未来几个月内价值激增。分析师对其未来持乐观态度。他们预测每股平均价格目标为 25.58 美元，根据最近 7.28 美元的股价，上涨了 230.92%。在预测的最高端，最乐观的分析师预计每股 34 美元，上涨 339.84%。</p>
</div><h2>Geron (GERN)</h2>
<div class="lb-trans"><h2>Geron (GERN)</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: shutterstock.com/Romix Image</p>
<div class="lb-trans"><p>来源：shutterstock.com/Romix Image</p>
</div><p><strong>Geron</strong>(NASDAQ: <strong>GERN</strong>) is a clinical biopharmaceutical company developing and commercializing blood cancer treatments. Its primary product, which is in Phase 3 clinical trials, is a telomerase inhibitor. It inhibits the progression of cancer cells in the blood.</p>
<div class="lb-trans"><p><strong>Geron</strong>（NASDAQ：<strong>GERN</strong>）是一家临床生物制药公司，致力于开发和商业化血液癌症治疗。其主要产品是处于第 3 期临床试验中的端粒酶抑制剂。它抑制了血液中的癌细胞的进展。</p>
</div><p>In June, Geron announced the approval of Rytelo (Imetelstat) for use in patients with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia.</p>
<div class="lb-trans"><p>6 月，Geron 宣布获得 Rytelo（Imetelstat）在患有输血依赖性贫血的低风险骨髓增生异常综合征（MDS）患者中使用的批准。</p>
</div><p>According to its fiscal first quarter results, the company has $465 million in liquidity, giving it plenty of space to maneuver and support existing trials. It also grew revenue significantly to $304,000 compared to $21,000 in the first quarter of 2023.</p>
<div class="lb-trans"><p>根据其 2024 财年第一季度业绩，该公司拥有 4.65 亿美元的流动性，为其提供了充足的空间来操作和支持现有试验。与 2023 年第一季度的 21,000 美元相比，其收入也大幅增长至 304,000 美元。</p>
</div><p>The company also forecasts that it still has enough resources to support operations until the second quarter of 2026. Following the approval of Imetelstat for use in the U.S., it is likely the company will improve its revenue outlook in Q2.</p>
<div class="lb-trans"><p>该公司还预测，它仍有足够的资源支持运营，直到 2026 年第二季度。在 Imetelstat 获得在美国使用批准后，该公司可能会改善其第二季度的收入前景。</p>
</div><p>Imetelstat is a direct competitor to <strong>Merck</strong> (NYSE: <strong>MRK</strong>) and <strong>Bristol-Myers Squibb</strong> (NYSE: <strong>BMY</strong>) products. That makes Geron a prime candidate for a buyout. Given that oncology merger and acquisition activity is quite popular in the healthcare space, GERN investors could see a huge boost in share price in case of a buyout. Analysts are quite optimistic about GERN. They give the stock an average price target of $6.81, a 63.31% upside based on the most recent price of $4.53 per share. At the high end of the forecast, analysts forecast $10, a 139.81% upside.</p>
<div class="lb-trans"><p>Imetelstat 是 <strong>Merck</strong>（NYSE：<strong>MRK</strong>）和 <strong>Bristol-Myers Squibb</strong>（NYSE：<strong>BMY</strong>）产品的直接竞争对手。这使得 Geron 成为被收购的主要候选公司。鉴于肿瘤学的并购活动在医疗保健领域非常流行，GERN 投资者在收购时可能会看到股价大幅提升。分析师对 GERN 持乐观态度。他们给予该股票平均价格目标为 6.81 美元，根据最近 4.53 美元的股价，上涨了 63.31%。在预测的最高端，分析师预测 10 美元，上涨了 139.81%。</p>
</div><p><em>On the date of publication, Joel Lim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p><em>在发布日期，Joel Lim 在本文提到的证券中没有（直接或间接）任何头寸。本文中表达的观点属于作者本人，遵守 InvestorPlace.com 的发布准则。</em></p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在发布日期，负责编辑在本文提到的证券中没有（直接或间接）任何头寸。</em></p>
</div><p>Joel Lim is a contributor at InvestorPlace.com and a finance content contractor who creates content for several companies like LTSE and Realtor, along with financial publications, including Business Insider, Yahoo Finance, Mises Institution and Foundation for Economic Education.</p>
<div class="lb-trans"><p>Joel Lim 是 InvestorPlace.com 的撰稿人，也是一名金融内容承包商，为 LTSE 和 Realtor 等多家公司以及 Business Insider、Yahoo Finance、Mises Institution 和 Foundation for Economic Education 等金融出版物创作内容。</p>
</div><p>Healthcare, Biotech</p>
<div class="lb-trans"><p>医疗保健、生物科技</p>
</div><p>Growth Stocks, Undervalued Stocks</p>
<div class="lb-trans"><p>成长股、低估股票</p>
</div>

3 只价格低于 10 美元的生物科技股票可能让你致富